SCIOSCIA, CRESCENZIO
 Distribuzione geografica
Continente #
NA - Nord America 4.718
AS - Asia 1.597
EU - Europa 1.228
SA - Sud America 355
AF - Africa 56
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.962
Nazione #
US - Stati Uniti d'America 4.647
SG - Singapore 731
CN - Cina 344
BR - Brasile 283
SE - Svezia 268
RU - Federazione Russa 225
HK - Hong Kong 185
DE - Germania 172
FR - Francia 153
GB - Regno Unito 93
FI - Finlandia 90
VN - Vietnam 86
IT - Italia 85
IN - India 56
BE - Belgio 39
CA - Canada 38
AR - Argentina 35
BD - Bangladesh 31
IQ - Iraq 26
UA - Ucraina 23
MX - Messico 22
TR - Turchia 20
PL - Polonia 18
CI - Costa d'Avorio 16
ID - Indonesia 16
SA - Arabia Saudita 15
ZA - Sudafrica 15
IR - Iran 12
JP - Giappone 11
PK - Pakistan 11
NL - Olanda 10
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
IE - Irlanda 9
PH - Filippine 8
VE - Venezuela 8
CO - Colombia 7
EC - Ecuador 7
ES - Italia 7
AT - Austria 6
CL - Cile 6
PY - Paraguay 6
LT - Lituania 5
NP - Nepal 5
OM - Oman 5
AU - Australia 4
AZ - Azerbaigian 4
ET - Etiopia 4
TH - Thailandia 4
TN - Tunisia 4
AL - Albania 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
MA - Marocco 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
PA - Panama 2
PS - Palestinian Territory 2
SN - Senegal 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
EE - Estonia 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
MM - Myanmar 1
MN - Mongolia 1
MP - Marianne Settentrionali, isole 1
MT - Malta 1
MW - Malawi 1
NG - Nigeria 1
PE - Perù 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
ZW - Zimbabwe 1
Totale 7.962
Città #
Ashburn 515
Fairfield 487
Chandler 449
Singapore 405
Woodbridge 326
Seattle 269
Houston 265
Ann Arbor 253
Nyköping 227
San Jose 213
Cambridge 197
Hong Kong 184
Wilmington 164
Beijing 150
New York 76
Dearborn 68
Dallas 63
Munich 63
Lawrence 62
Roxbury 62
Jacksonville 61
Lauterbourg 54
Los Angeles 52
Helsinki 44
Des Moines 39
Brussels 38
Inglewood 38
Brooklyn 36
Moscow 36
Nanjing 34
Paris 30
Santa Clara 30
Ho Chi Minh City 29
San Diego 27
Turku 26
Bari 24
Boardman 22
London 22
São Paulo 22
Princeton 19
Redwood City 17
Warsaw 17
Abidjan 16
Council Bluffs 16
Hanoi 16
Hebei 16
Orem 15
Toronto 15
Buffalo 14
Poplar 13
Chicago 11
Frankfurt am Main 11
Montreal 11
Mumbai 11
Atlanta 10
Denver 10
Stockholm 10
The Dalles 10
Tokyo 10
Falkenstein 9
San Francisco 9
Shenyang 9
Tashkent 9
Baghdad 8
Boston 8
Columbus 8
Dublin 8
Shanghai 8
Washington 8
Belo Horizonte 7
Brasília 7
Campinas 7
Guangzhou 7
Riyadh 7
San Mateo 7
Amsterdam 6
Chennai 6
Haiphong 6
Hefei 6
Jakarta 6
Jiaxing 6
Jinan 6
Johannesburg 6
Kunming 6
Mexico City 6
Ottawa 6
Ardabil 5
Augusta 5
Brno 5
Changsha 5
Da Nang 5
Isidro Casanova 5
Lahore 5
Leawood 5
Manchester 5
Muscat 5
New Delhi 5
Nuremberg 5
Querétaro 5
Quito 5
Totale 5.692
Nome #
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 187
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 183
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 175
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 172
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 165
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 164
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 161
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 155
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 154
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 153
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 152
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 152
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 147
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 146
Old and new antirheumatic drugs and the risk of hepatotoxicity 146
Diffusion and applications of musculoskeletal ultrasound in Italian Rheumatology Units 145
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 144
A knowledge-based framework enabling decision support in RFID solutions for healthcare 142
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 142
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 136
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 136
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 133
AB1114 Three Years Experience with “Sustain”, an Extra-Hospital Infusion Programme for Patients with Rheumatoid Arthritis Treated with Abatacept 133
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 129
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 129
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 127
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 127
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 126
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 125
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 122
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 114
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 114
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 114
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 113
Ultrasonography in the diagnosis and management of patients with inflammatory arthritides 112
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 112
The italian MSUS study group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatology 107
SAT0380 FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS 107
OP0217 Ultrasound-Detected Synovitis and Tenosynovitis Independently Associate with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 103
null 101
Infliximab therapy in patients with rheumatic disease and HCV chronic infection 101
SAT0061 Concurrent Ultrasound-Detected Synovitis and Tenosynovitis Predict Flare in Patients with Rheumatoid Arthritis in Clinical Remission 101
null 97
Integrin expression on human osteoblasts in osteoarthritis 97
Osteocalcin production by osteoarthritic osteoblasts after vitamin D stimulation 96
COMP serum levels in patients with rheumatoid arthritis before and after infliximab therapy 95
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 90
The treatment of recurrent uveitis with TNF-alpha inhibitors 87
Leukocytoclastic vasculitis as onset symptom of ulcerative colitis 84
Increased Bcl-2/p53 ratio in human articular cartilage: a possible role in regulation of chondrocyte metabolism 84
null 84
Economical Evaluation of the Sustain Program for the Out-of-Hospital Administration of Abatacept for Rheumatoid Arthritis 84
null 82
null 82
Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis 80
null 79
Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) (Clinical Rheumatology, (2018), 37, 3, (667-675), 10.1007/s10067-018-3989-2) 77
Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: Results by Italian DELphi in psoriatic arthritis (IDEA) 75
Ultrasonography in psoriatic arthritis: Which sites should we scan? 74
null 73
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review 73
Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 67
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey 67
null 66
Use of etanercept in the treatment of dermatomyositis: a case series 64
Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients 63
L'obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après échec d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde 62
Repeated infusions of low-dose infliximab plus methotrexate in psoriathic arthrtritis: immediate benefitis are not maintained after discontinuation of inlfiximab 54
null 53
Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: Results from the observational study STARTER of the Italian Society for Rheumatology 51
Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy 48
null 46
null 45
The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: The STARTER study 45
null 44
Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study 25
Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors 14
Totale 8.114
Categoria #
all - tutte 32.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.048


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 0 0 0 0 0 0 79 60 41
2021/2022537 39 41 8 25 26 40 15 23 24 44 79 173
2022/20231.034 114 150 82 116 113 130 29 108 144 10 23 15
2023/2024252 18 57 15 22 19 59 4 13 4 8 2 31
2024/20251.250 24 21 101 44 12 100 120 167 54 78 198 331
2025/20262.301 398 114 124 247 374 179 279 63 341 182 0 0
Totale 8.114